Literature DB >> 8010370

Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors.

R Bergeron1, P Blier.   

Abstract

A low dose of cisapride (5 mg b.i.d.) produced rapid relief from nausea elicited by the initiation of treatment with a selective serotonin reuptake inhibitor in eight patients. This effect of cisapride is presumably related to its serotonin3 antagonistic property.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8010370     DOI： 10.1176/ajp.151.7.1084

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  8 in total

Review 1.  Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.

Authors:  Brian Draper; Karen Berman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 3.  New perspectives in antiemetic treatment.

Authors:  J Herrstedt
Journal:  Support Care Cancer       Date:  1996-11       Impact factor: 3.603

4.  Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs.

Authors:  P Blier; C Bouchard
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

5.  DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats.

Authors:  Taro Kato; Yuji Matsumoto; Masanori Yamamoto; Kenji Matsumoto; Satoko Baba; Keiko Nakamichi; Harumi Matsuda; Haruka Nishimuta; Kazuki Yabuuchi
Journal:  Pharmacol Res Perspect       Date:  2015-05-08

Review 6.  A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.

Authors:  Gareth J Sanger; Paul L R Andrews
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

7.  Oral mosapride can provide additional anti-emetic efficacy following total joint arthroplasty under general anesthesia: a randomized, double-blinded clinical trial.

Authors:  Jinwei Xie; Yingchun Cai; Jun Ma; Qiang Huang; Fuxing Pei
Journal:  BMC Anesthesiol       Date:  2020-12-03       Impact factor: 2.217

8.  Rikkunshi-to attenuates adverse gastrointestinal symptoms induced by fluvoxamine.

Authors:  Takakazu Oka; Yoko Tamagawa; Sota Hayashida; Yuko Kaneda; Naoki Kodama; Sadatoshi Tsuji
Journal:  Biopsychosoc Med       Date:  2007-11-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.